The clinical trials of rituximab have yielded a number of observations and correlations regarding its mechanism of action. These include the level of CD20 antigen expression, the histology of the tumor, the observed pharmacokinetics and half-life of the antibody in the serum and tumor, the influen...
Rituximab has been applied successfully in the treatment of indolent and aggressive CD20 positive B cell lymphomas, yet the exact in vivo mechanisms of its action have not been unambiguously explained. This study was therefore aimed to confirm the presumed major mechanisms of action of rituximab and...
[2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54. [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of c...
产品活性:Rituximab 是一种抗 CD20 嵌合单克隆抗体,用于某些自身免疫疾病和癌症的研究。 生物活性:利妥昔单抗是一种抗 CD20 嵌合单克隆抗体,用于治疗某些自身免疫性疾病和癌症类型。体外利妥昔单抗抑制受刺激的人类 B 细胞的增殖,这与具有活化的幼稚表型的 B 细胞的相对增加有关。除了这种人口转变之外,各种 B 细胞...
The Fab region gives rituximab its specificity for CD20, while the Fc region interacts with cell surface receptors to activate the immune system, leading to the depletion of circulating B lymphocytes 6. In regards to the mechanism of action in rheumatoid arthritis (RA), B-cells are thought to...
产品活性:Rituximab 是一种抗 CD20 嵌合单克隆抗体,用于某些自身免疫疾病和癌症的研究。 生物活性:利妥昔单抗是一种抗 CD20 嵌合单克隆抗体,用于治疗某些自身免疫性疾病和癌症类型。体外利妥昔单抗抑制受刺激的人类 B 细胞的增殖,这与具有活化的幼稚表型的 B 细胞的相对增加有关。除了这种人口转变之外,各种 B 细胞...
The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.doi:10.1634/theoncologist.2008-0089Rituximab, a genetically engineered chimeric monoclonal antibody specifically binding to CD20, was the first antibody approved by the U.S. Food and Drug ...
Structure & Mechanism of Action Rituximab is a chimeric IgG1 monoclonal antibody created by fusing the light and heavy chain variable domains of 2B8, a murine monoclonal anti-CD20 antibody, and human α-light chain and γ1-heavy chain constant regions. Rituximab binds specifically to CD20 and ...
[2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1;101(3):949-54.[3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of ...
Obinutuzumab is a monoclonal antibody that targets the CD20 antigen on the surface o.. What is the mechanism of action and adverse reactions of Rituximab in the treatment of NHL?Non-Hodgkin lymphoma (NHL) is the most common form of blood cancer in adults, with B cells being the most ...